OSTAAT™ is a non-invasive connected medical device designed for people affected by osteopenia or osteoporosis, with or without associated severe chronic kidney disease.
The technology involves applying a low-intensity electric current with no side effects. The current acts on cell membrane mechanisms, allowing calcium to enter the cells, thus promoting bone growth. The technology can be used preventively, to reduce the risk of fractures of all kinds, or curatively, to accelerate the healing process of fractures* caused by osteoporosis, severe chronic kidney disease, or other conditions. At the cutting edge of technology, the OSTAAT™ device in its prototype belt version for clinical studies and its smart clothing version, will be able to be activated via a mobile app accessible on cell phone, tablet, or computer.
* Claims will be addressed in future clinical trials.
KAT Innovation's OSTAAT™ technology addresses an unmet need for over 850 million people worldwide with chronic kidney disease (CKD), including more than 135 million with severe CKD. This population has a high prevalence of osteoporosis, for which drug treatments are contraindicated. As a result, due to bone resorption, their bones become brittle, considerably increasing the risk of fractures and mortality associated with this comorbidity.
Faced with this difficult situation, which affects a significant proportion of the population, KAT Innovation offers an accessible, easy-to-use technology that finally meets an unmet need for these patients.
Meeting a critical need in chronic kidney disease
KAT Innovation's revolutionary OSTAAT™ technology addresses a pressing global health challenge affecting more than 850 million people worldwide with chronic kidney disease (CKD), including 135 million individuals battling severe CKD. This vast patient population faces a critical dilemma: a high prevalence of osteoporosis combined with contraindications to traditional drug therapies.
The bone health crisis in CKD
For patients with CKD, deteriorating bone health represents a serious threat. As bone resorption accelerates, their skeletal structure becomes increasingly fragile, greatly increasing the risk of fractures. This comorbidity not only diminishes quality of life, but also significantly increases mortality rates in this vulnerable group.
OSTAAT™: A revolutionary solution
In response to this urgent, unmet medical need, KAT Innovation has developed OSTAAT™ — an accessible, user-friendly technology. This innovative solution offers new hope to millions of CKD patients worldwide, providing an effective approach to managing bone health where conventional treatments fall short.
By offering an innovative alternative to traditional therapies, OSTAAT™ represents a potential paradigm shift in CKD patient care, filling a critical gap in current treatment options and potentially improving outcomes for millions of people worldwide.
The OSTAAT™ device uses a sophisticated low-intensity electrical current to stimulate bone growth. This innovative and patented* technology, the result of rigorous academic research, has undergone extensive studies to elucidate its mechanism of action on osteogenesis.
* Patents pending.
The scientific validation of OSTAAT™ is based on a comprehensive research program:
These multidimensional studies have demonstrated OSTAAT™'s potential as a non-pharmacological alternative for osteoporosis and bone disorders related to chronic kidney disease, particularly for patients intolerant to traditional drug treatments.
The discovery of a link between electrical stimulation and bone growth led to an exhaustive review of scientific literature, generating new hypotheses currently being studied in collaboration with university researchers.
An in vitro study, conducted in partnership with UQAM since August 2022, has confirmed the initial hypothesis on the link between electrical stimulation and bone formation. The results validate the device's voltage parameters, essential for stimulating ion channels responsible for calcium deposition in cells.
These advances will soon be presented at scientific conferences and published in international journals, marking a crucial step towards launching a multicenter clinical study.
OSTAAT™ technology represents a groundbreaking advancement in the treatment of osteopenia and osteoporosis with or without severe chronic kidney disease, offering a unique and innovative approach to bone health management.
By combining cutting-edge technology with a deep understanding of bone physiology, OSTAAT™ offers a safe, effective, and convenient alternative to traditional osteoporosis treatments.
OSTAAT™ technology shows promise in stimulating osteoblasts, counteracting osteoclast impact, and influencing H-type blood vessels crucial for bone homeostasis. This systematic approach aims to thoroughly validate this non-invasive bone growth technology, potentially offering a new treatment option for various bone-related conditions.
Our innovative approach to bone growth stimulation raised numerous questions regarding the effects of electrical stimulation on bone growth mechanisms. To address these, our scientific team conducted a comprehensive review of existing literature, identifying key areas for investigation.
Following this analysis, we initiated in vitro and ex vivo trials to elucidate and demonstrate the mechanisms of action of our OSTAAT™ technology. These preliminary investigations were designed to pave the way for future pilot and multicenter clinical trials, ultimately enabling us to validate the efficacy and safety of our device in human subjects.
Our trials focused on testing hypotheses formulated by our scientific team regarding the relationships between OSTAAT™ electrical stimulation and various bone-related processes:
Our scientists' hypotheses yielded promising results, suggesting that electrical stimulation OSTAAT™ at specific voltages influences cell membrane mechanisms, promoting calcium entry into bone cells and stimulating bone growth in a manner mimicking natural calcium influx pathways. These findings, currently confidential, will be the subject of forthcoming scientific publications.
The in vitro trials also addressed additional hypotheses, with results to be included in upcoming publications. This proof of concept has propelled us towards the next crucial phase: pilot and multicenter clinical trials involving patients with osteopenia, osteoporosis, or chronic kidney disease-related osteoporosis.
Preliminary results indicate a significant increase in bone mass using OSTAAT™, driving us towards more extensive clinical trials in collaboration with renowned institutions. Concurrently, we are exploring potential applications of our technology to support bone health in astronauts during extended space missions, offering a possible solution to bone density loss in microgravity environments.
Clinical Development of OSTAAT™
The clinical development of OSTAAT™ has followed a systematic approach, progressing from preliminary studies to planned human trials.
Current Focus: In Vitro and Ex Vivo Trials
Next Steps: Clinical Studies
Future Projects
These studies will validate our OSTAAT™ technology under various clinical conditions and explore its potential in cutting-edge fields such as space medicine.
Note: Submission of scientific articles for publication is scheduled for the first quarter of 2025. Detailed technical reports ("White Papers") are available upon request from our research team.
